Largecap pharma, barring Dr Reddy’s, overvalued: Prabhudas
Discussing his outlook on pharma names, Pal said that he expects only a 10-12 percent growth in Lupin’s stock. Rating agencies Credit Suisse and Nomura had upgraded their ratings on the stock recently.